Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + pentoxifylline
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of metformin, a biguanide antihyperglycemic agent, and pentoxifylline, a methylxanthine derivative. Metformin works by decreasing hepatic glucose production, reducing intestinal glucose absorption, and increasing insulin sensitivity. Pentoxifylline improves blood circulation by reducing blood viscosity and improving red blood cell flexibility. The combination has shown efficacy in treating nonalcoholic steatohepatitis and endometriosis-related conditions, particularly endometrioma in infertile women.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ADORA2A (Adenosine A₂A Receptor)ND1 (Mitochondrial electron transport chain complex I)PDE (Phosphodiesterase family)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on metformin + pentoxifylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + pentoxifylline.